Drug Type Biological products |
Synonyms PNT 001 |
Target |
Mechanism TAU inhibitors(Microtubule-associated protein tau inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Pinteon Therapeutics, Inc.Startup |
Active Organization- |
Inactive Organization Pinteon Therapeutics, Inc.Startup |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Start Date29 Mar 2021 |
Sponsor / Collaborator Pinteon Therapeutics, Inc.Startup [+1] |
Start Date17 Sep 2019 |
Sponsor / Collaborator Pinteon Therapeutics, Inc.Startup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Injuries, Traumatic | Phase 1 | US | Pinteon Therapeutics, Inc.Startup | 29 Mar 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | - | 49 | ybttabosim(snxfauezyn) = Three non-serious Grade 1 adverse events were determined to be related to PNT001 or placebo, and all resolved without sequelae. ipucrnthid (gwxgfwzevp ) View more | Positive | 01 Feb 2021 | ||
Placebo |